



AKINow Panel:

How to Build and Best Use Kidney Biorepositories

April 18, 2024




1



Welcome

LESLIE S. GEWIN, MD



2



Agenda

Introductory Remarks

Leslie Gewin, MD

Panel Discussion

Adriana M. Hung, MD, MPH

Sanjay Jain, MD, PhD

Chirag R. Parikh, MD, PhD, FASN

Audience Q&A

Leslie S. Gewin, MD and panelists

Closing Remarks

Leslie S. Gewin, MD



3



Zoom Housekeeping



Presentation will last 60 minutes.



Session is recorded.

Recording and resources will be uploaded onto the EPC website.



Audio is muted.
Use the Q&A icon or chat function to ask the presenters questions and read their responses.



How did we do?

Survey will be shown at the end of the webinar.



4



Disclaimer

This AKINow panel discussion is provided as information and education and should not be construed as medical advice or recommendations for patient care. The information expressed is that of the speaker(s) and contributor(s) only. Clinicians are to use their own training, clinical observations, and judgment to make all diagnostic and treatment decisions. The ASN Alliance (including ASN) does not offer medical advice.



5



Faculty Disclosures

Leslie S. Gewin, MD

Employer: Washington University in St. Louis School of Medicine, St. Louis VA Hospital

Research Funding: NIH, VA; Longer Life Foundation

Honoraria: Daiichi Sankyo

Advisory or Leadership Role: Editorial boards for JASN, Kidney360, and American Journal of Physiology Renal Physiology, and Frontiers in Nephrology; External Scientific Advisor, Kidney Institute of New Mexico; Executive Council for Women in Nephrology and Council member for Southern Society of Clinical Investigation, member of AKINow Workgroups

Adriana M. Hung, MD, MPH

Employer: Vanderbilt University and Veterans Affairs

Research Funding: VHA CSR&D Merit "Genetics of Kidney Disease & Hypertension, Risk Prediction and Drug Response"; Vertex Grant to VUMC

Advisory or Leadership Role: Co-Chair, Million Veteran Program (MVP) Publication and Presentations Committee and Co-chair of the MVP Phenomic Working Group

Sanjay Jain, MD, PhD

Employer: Washington University in St. Louis School of Medicine

Advisory or Leadership Role: HUBMAP, KPMP

Chirag R. Parikh, MD, PhD, FASN

• **Employer:** Johns Hopkins Medicine

• **Ownership Interest:** Renalytix

• **Research Funding:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Heart, Lung and Blood Institute (NHLBI)

• **Advisory or Leadership Role:** Principal Investigator: TRIBE-AKD Network; Steering Committee, KPMP



6




Panel discussion

Leslie S. Gewin, MD
Moderator

AKI*NOW*


 **ASN**
American Society of Nephrology

7




PANELISTS


Panelists



Adriana M. Hung
MD, MPH




Sanjay Jain
MD, PhD




Chirag R. Parikh
MD, PhD, FASN

AKI*NOW*

 **ASN**
American Society of Nephrology






8




How to build and best use kidney biorepositories

Sanjay Jain MD, PhD
sanjayjain@wustl.edu
 Professor, Medicine (Nephrology)
 Director, Kidney Translational Research Center – KTRC

- *Who is it for?*
- *How to make it happen?*
- *Do we need to think about applications not currently perceived?*
- *Can we sustain it?*









9




GENERAL POINTS


Purpose	Source	Factors
<ul style="list-style-type: none"> • Cell diversity • Gene networks • Cell throughput • Cell rarity • Pathobiology • Biomarkers • Validations 	<ul style="list-style-type: none"> • Deceased Donor • Living Donor • Surgical Resection • Biopsy • Fluid samples <div style="margin-top: 10px;"> $f(\text{trash}) = \text{trash}$ $f(\text{trash}) = \text{trash}^2$ $f(\text{trash}) = \text{trash}^3$ </div>	<ul style="list-style-type: none"> • Accessibility • Patient burden • Metadata – general health • Sampling • Timely preservation • QA/QC in place • Infrastructure – sample longevity • Broad sharing • Standardized protocols • Costs


10



11



12



13

National repositories (MVP, BioVU) versus building your own repository



*Adriana M. Hung
Professor of Medicine
Vanderbilt Precision Nephrology - KidPhenGen
Division of Nephrology and Hypertension
Vanderbilt University Medical Center*

ASN
American Society of Nephrology

14

The Million Veteran Program: > 1,000,000 participants

❖ Clinical cohort of US military veterans enrolled at 65 (~80 VAMC) since 2011

Chief, Division of Aging
Professor, Harvard Medical
School

San Juan: 193

Honolulu

Central Texas: 5,911

Denver: 4,202


Kansas City: 3,390

Tuscaloosa: 4,003

San Francisco: 2,858

West Haven: 4,513

* = Actively Recruiting
• = Closed to Recruitment



American Society of Nephrology

15

The Million Veteran Program: Diversity in genetics

Genetically inferred ancestry in Participants with DNA (release 4: 658,220)

Ancestry	Count	Percentage
EUR	457,475	70%
AFR	123,260	19%
AMR	61,073	9%
SAS	8,761	1%
Other	7,073	1%
EAS	578	0%


Patient Count for APOL1 in MVP

Risk Category	Count
no risk alleles	49,908
one risk allele	56,289
two risk alleles	15,745
All	121,942

The role of APOL1 in AKI in patients with COVID-19

The characterization of N264K a protective variant that represent the genetic proxy of an APOL1 blocker

The role of G6PD deficiency in diabetes complications.



American Society of Nephrology

16



Current Omics Plans

- ❑ Genotyping for all MVP sample (n=658,220 for release 4)
 - MVP array (Affymetrix +custom chosen)
- ❑ WGS: 182,000 (10K pilot 80x)
- ❑ Methylation: 42,000 (currently available)
 - MVP array (Affymetrix +custom chosen)
 - MVP Ethic array
- Exomes: 250,000
- Metabolomics: 20,000 to 10,000
- Proteomics (pilot on 1000 individuals)



17



Million Veteran Program (MVP)

- Enroll up to one million users of the VHA into an observational mega-cohort
 - Blood collection for storage in biorepository for future research
 - Collect self-reported health and lifestyle information
 - Access to electronic medical record
 - Ability to recontact participants




Million Veteran Program


VETERANS HEALTH ADMINISTRATION



18



19



VA has created a data commons that is aimed to non-VA investigators; will be available in the near future

20

9 r> #r# r q #li · #h
> C dyIt d #h#r k #<v#k#hqr~ jivylruqdr y%
> . uhd#h#q#ljjr · q#
> Q · i ~ l#r · u#khqr #<h# vlqt # · u#
<khqr #<h# hi sr~

CIPHER@va.gov | phenomics.va.ornl.gov

[Million Veteran Program \(MVP\) \(va.gov\)](#)

VA | U.S. Department of Veterans Affairs


ASN
American Society of Nephrology

21


https://www.mvp.va.gov/pwa/joinmvp

Join the Million Veteran Program


Any Veteran can join MVP online.




Step 1. Securely sign in through one of our sign-in partners like MyHealtheVet, DS Logon, LOGIN.gov, or ID.me.



Step 2. Complete the consent process and allow our program access to your health records.



Step 3. Provide a blood sample, either by mail or by scheduling an appointment at a participating VA.




Step 4. Complete Surveys about health, lifestyle, military experiences, and exposures.

[Join today](#)




Prefer to join our program in-person? Call 866-441-6075 to make an appointment at a participating VA.

ASN
American Society of Nephrology

22




Synthetic Derivative vs. BioVU

 <p>98,000 people with MEGA 35,000 AA with WGS 250,000 participants with WGS data</p> <p>Synthetic Derivative ~1.9 million</p>	 +  <p>BioVU ~135,000</p>
--	--

ASN
American Society of Nephrology


23



Question & collaborations:

Kidney Phenomics & Genomics (KidPhenGen) / Precision Nephrology

Understanding the genetic and environmental factors that contribute to chronic kidney disease (CKD) progression and outcomes in CKD to improve the care we provide through personalize medicine and reduce kidney outcomes inequalities



Precision phenomics

- VA e-kidney Bx repository
- Progression phenotypes
- Phenomics risk score (pair WGS)
- Urine/ imaging/ discovery.

Discovery & integrative Omics

- GWAS/WES/WGS and fine mapping
- Transcriptomic/metabolomics/proteomics/epigenetics
- Functional genomics

Precision prescribing

- Pharmacoepidemiology
- Emulation trials
- Pharmacogenomics
- MR & the druggable genome


Individual risk prediction & Environmental exposures

- PRSs/ Epidemiology & Outcomes
- Mobile/Fitbit/etc
- Implementation/ROR


email: Adriana.Hung@yumc.org

ASN
American Society of Nephrology


24



25




26



Thank you for attending today's
AKINow panel discussion!

*Please contact ASN with any questions:
Email: epc@asn-online.org
Website: epc.asn-online.org*

AKI*NOW*

 **ASN**
American Society of Nephrology